Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | F11 | P03951 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.33 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.33 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17350058 | 0.86 | F11 (0.43) | ARF11KLK7MAPTGAA | |
| SCHEMBL13720553 | 0.86 | MAPT (0.37) | ARF11LTA4HPKMKLK7 | |
| SCHEMBL13828839 | 0.80 | CTSS (0.39) | ARPKMMAPTALDH1A1GFER | |
| SCHEMBL13721071 | 0.80 | MAPT (0.37) | ARF11LTA4HPKMMAPT | |
| SCHEMBL13721062 | 0.77 | AR (0.38) | ARPKMMAPTHRH3ALDH1A1 | |
| SCHEMBL15671653 | 0.76 | AR (0.36) | ARF11LTA4HPKMMAPT | |
| SCHEMBL13721677 | 0.76 | AR (0.38) | ARF11LTA4HMAPTHTR2C | |
| SCHEMBL1980293 | 0.75 | AR (0.41) | ARPKMMAPTHRH3ALDH1A1 | |
| SCHEMBL12594172 | 0.75 | LTA4H (0.42) | ARF11LTA4HMAPTALDH1A1 | |
| SCHEMBL20567481 | 0.75 | LTA4H (0.42) | ARF11LTA4HMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | AR 4850/4885F11 3428/4885LTA4H 1839/4885 |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | AR 4780/4885F11 1896/4885LTA4H 4140/4885 |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | AR 4780/4885F11 1896/4885LTA4H 4140/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | AR 4780/4885F11 1896/4885LTA4H 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.